share_log

Tharimmune | ARS: Annual Report to Security Holders

Tharimmune | ARS: Annual Report to Security Holders

Tharimmune | ARS：年度報告
美股sec公告 ·  03/22 23:12
牛牛AI助理已提取核心訊息
Tharimmune, Inc., a clinical-stage biotechnology company, announced the signing of a patent license agreement with Avior Inc. on November 3, 2023, granting exclusive rights to develop, manufacture, and commercialize therapeutic candidates TH104 and TH103 globally. The FDA approved an IND application for TH104 in February 2023, targeting chronic pruritis in primary biliary cholangitis (PBC) patients. Tharimmune is also advancing an early-stage pipeline focusing on immuno-oncology targets such as HER2, HER3, and PD-1. The company's financial statements for the year ended December 31, 2023, indicate a net loss of $9.3 million, with research and development expenses increasing due to pre-clinical activities and licensing fees. Tharimmune raised approximately $13.6 million through public offerings to support operations. The company's future plans include clinical trials for TH3215 and TH1940, with the need for additional funding to continue operations, raising substantial doubt about its ability to continue as a going concern.
Tharimmune, Inc., a clinical-stage biotechnology company, announced the signing of a patent license agreement with Avior Inc. on November 3, 2023, granting exclusive rights to develop, manufacture, and commercialize therapeutic candidates TH104 and TH103 globally. The FDA approved an IND application for TH104 in February 2023, targeting chronic pruritis in primary biliary cholangitis (PBC) patients. Tharimmune is also advancing an early-stage pipeline focusing on immuno-oncology targets such as HER2, HER3, and PD-1. The company's financial statements for the year ended December 31, 2023, indicate a net loss of $9.3 million, with research and development expenses increasing due to pre-clinical activities and licensing fees. Tharimmune raised approximately $13.6 million through public offerings to support operations. The company's future plans include clinical trials for TH3215 and TH1940, with the need for additional funding to continue operations, raising substantial doubt about its ability to continue as a going concern.
處於臨床階段的生物技術公司Tharimmune, Inc. 於2023年11月3日宣佈與Avior Inc.簽署專利許可協議，授予在全球開發、製造和商業化候選藥物 TH104 和 TH103 的獨家權利。美國食品藥品管理局於 2023 年 2 月批准了 TH104 的臨床試驗申請，該申請針對的是原發性膽源性膽管炎 (PBC) 患者的慢性瘙癢症。Tharimmune還在推進以免疫腫瘤學靶點（例如HER2、HER3和PD-1）爲重點的早期產品線。該公司截至2023年12月31日止年度的財務報表顯示淨虧損930萬美元，由於臨床前活動和許可費，研發費用增加。Tharimmune通過公開募股籌集了約1,360萬美元以支持運營。該公司的未來計劃包括 TH3215 和 TH1940 的臨床試驗，需要額外的資金才能繼續運營，這引發了人們對其持續經營能力的嚴重懷疑。
處於臨床階段的生物技術公司Tharimmune, Inc. 於2023年11月3日宣佈與Avior Inc.簽署專利許可協議，授予在全球開發、製造和商業化候選藥物 TH104 和 TH103 的獨家權利。美國食品藥品管理局於 2023 年 2 月批准了 TH104 的臨床試驗申請，該申請針對的是原發性膽源性膽管炎 (PBC) 患者的慢性瘙癢症。Tharimmune還在推進以免疫腫瘤學靶點（例如HER2、HER3和PD-1）爲重點的早期產品線。該公司截至2023年12月31日止年度的財務報表顯示淨虧損930萬美元，由於臨床前活動和許可費，研發費用增加。Tharimmune通過公開募股籌集了約1,360萬美元以支持運營。該公司的未來計劃包括 TH3215 和 TH1940 的臨床試驗，需要額外的資金才能繼續運營，這引發了人們對其持續經營能力的嚴重懷疑。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。